Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity

SEMAFOLLOW - Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity: Observational, National Cohort, Real-world Study in France

SEMAFOLLOW is a real-world follow-up study examining the outcomes of individuals treated with WEGOVY® (semaglutide 2.4 mg) under the temporary authorisation for use (ATU) and early access programme in France. This study evaluates weight change, treatment strategies and well-being, drawing on the expertise of teams from various specialist obesity centres in France.

Inclusion Criteria:

• Patients included in the ATU/early access program for WEGOVY with at least two dispenses of WEGOVY
• No objection to the use of their data
• Patients able to complete an online questionnaire (via the internet)

Exclusion Criteria:

• Protected patients: minors, adults under guardianship, conservatorship, and/or legal protection